Methods Of Administration And Treatment
OwnerChun-fang Xuinventor
Life of this patent
Estimating the term…
Abstract
The present invention is directed to methods of administering pazopanib or pharmaceutically acceptable salts or solvates thereof as well as methods of treating cancer and age-related macular degeneration in patients in need thereof.
Claims49
A method of prescribing a compound of formula (I) to a Caucasian patient in need thereof, said method comprising:
- determining whether said patient has the TT genotype at the rs2858996 and/or rs707889 reference single nucleotide polymorphism;
- and
- if said patient does not have the TT genotype at the rs2858996 and/or rs707889 reference single nucleotide polymorphism, prescribing to said patient a compound of formula (I):
- or a pharmaceutically acceptable salt or solvate thereof.
A method of administering a compound of formula (I) to a Caucasian patient in need thereof, said method comprising:
- determining whether said patient has the TT genotype at the rs2858996 and/or rs707889 reference single nucleotide polymorphism;
- and
- if said patient does not have the TT genotype at the rs2858996 and/or rs707889 reference single nucleotide polymorphism, administering to said patient a compound of formula (I):
- or a pharmaceutically acceptable salt or solvate thereof.
A method of treating cancer in a Caucasian patient in need thereof, said method comprising:
- determining whether said patient has the TT genotype at the rs2858996 and/or rs707889 reference single nucleotide polymorphism;
- and
- if said patient does not have the TT genotype at the rs2858996 and/or rs707889 reference single nucleotide polymorphism, administering to said patient a compound of formula
- or a pharmaceutically acceptable salt or solvate thereof.
A method of treating cancer in a Caucasian patient in need thereof, said method comprising:
- administering to said patient a compound of formula (I):
- or a pharmaceutically acceptable salt or solvate thereof;
- and then
- determining whether said patient has the TT genotype at the rs2858996 and/or rs707889 reference single nucleotide polymorphism.
A method of treating cancer in a Caucasian patient in need thereof, said method comprising:
- administering to said patient a compound of formula (I):
- or a pharmaceutically acceptable salt or solvate thereof;
- and then
- determining whether said patient has a significant elevation in alanine aminostransferase.
A method of treating cancer in a Caucasian patient in need thereof, said patient genotyped as not having the TT genotype at the rs2858996 and/or rs707889 reference single nucleotide polymorphism, said method comprising:
- administering to said patient a compound of Formula (I):
- or a pharmaceutically acceptable salt or solvate thereof.
A method of treating cancer in a Caucasian patient in need thereof, said patient genotyped as not having at least one single nucleotide polymorphism that is correlated with the TT genotype of the rs2858996 and/or rs707889 reference single nucleotide polymorphism, said method comprising:
- administering to said patient a compound of Formula (I):
- or a pharmaceutically acceptable salt or solvate thereof.
A method of treating cancer in a Caucasian patient in need thereof, said method comprising:
- determining whether said patient has the TT genotype at the rs2858996 and/or rs707889 reference single nucleotide polymorphism;
- administering to said patient a compound of formula (I):
- or a pharmaceutically acceptable salt or solvate thereof;
- and then
- determining whether said patient has a significant elevation in alanine aminostransferase.
A method of screening a Caucasian human subject as an aid in predicting elevation in alanine aminotransferase (ALT) after administration of at least one dose of Formula I, or a pharmaceutically acceptable salt or solvate thereof, comprising:
- determining whether said patient has the TT genotype at the rs2858996 and/or rs707889 reference single nucleotide polymorphism, wherein the presence of at least one TT genotype indicates the subject is at increased risk for increased ALT after administration of Formula I, or a pharmaceutically acceptable salt or solvate thereof.
A method of screening a Caucasian human subject as an aid in predicting elevation in alanine aminotransferase (ALT) after administration of at least one dose of Formula I, or a pharmaceutically acceptable salt or solvate thereof, comprising:
- determining whether said patient has at least one single nucleotide polymorphism that is correlated with the TT genotype of the rs2858996 and/or rs707889 reference single nucleotide polymorphisms, wherein the presence of at least one single nucleotide polymorphism correlated with the TT genotype indicates the subject is at increased risk for increased ALT after administration of Formula I, or a pharmaceutically acceptable salt or solvate thereof.
A method of identifying a Caucasian human subject at increased risk of experiencing increased alanine aminotransferase (ALT) greater than or equal to three time upper limit normal after administration of at least one dose of Formula I, or a pharmaceutically acceptable salt or solvate thereof, comprising:
- performing a genotyping technique on a biological sample from said subject to determine whether the subject has at least one single nucleotide polymorphism that is correlated with the TT genotype of the rs2858996 and/or rs707889;
- detecting at least one single nucleotide polymorphism that is correlated with the TT genotype of the rs2858996 and/or rs707889;
- and
- correlating the detection of at least one single nucleotide polymorphism that is correlated with the TT genotype of the rs2858996 and/or rs707889 with an increased risk of experiencing increased ALT greater than or equal to 3×ULN to at least one dose of Formula I, or a pharmaceutically acceptable salt thereof, compared to the risk if no single nucleotide polymorphism that is correlated with the TT genotype of the rs2858996 and/or rs707889 were detected.
Dependencies are inferred from the claim text.